Forty days.

Six reasons the ED product is the play now

1. The GLP-1 price floor ate the margin.His $149 became the category default within a year, then $99, then $89. On a $149 plan the clinical partner keeps roughly two thirds. There is no room left to buy a customer at scale.
2. The window closed and the letters arrived.Mass compounding of semaglutide ended with the shortage in February 2025. The FDA sent more than fifty letters in 2026, one of them to him. ED compounding does not depend on a shortage exemption.
3. A man buying ED medication is a better customer than a dieter.He does not want a conversation, he wants a plain box. He pays $179 without asking about insurance. He reorders monthly for years. Nobody posts a before-and-after.
4. Meta lets you say age out loud.Weight is a health condition Meta will not let you target or imply. Age is not. “Born before 1972? Your price just dropped.” Veterans by age bracket. Older buyers, cheaper impressions, higher lifetime value.
5. The story writes itself.The 2,000-word first-person ad about five doctors and one blue pill is the highest-impression ad in the whole set. Shame, a spouse, a mechanism with four parts, a timestamped first night. GLP-1 stories had to dance around weight. This one does not.
6. Same machine, new product.The clinical partner already stocks it. The quiz funnel is identical: three questions, a verdict, the partner’s intake. Nothing had to be rebuilt except the ads.

Three layers again, and the hooks that carry it

• Brand page. QUAD Men’s Health. Birth-year pricing: “prices are set by birth year, the older you are, the better your rate.”
• Review pages that look like press. Modern Man Cave, Health Trends 24/7, TrendSeeker. “We tested 5 ED treatments. Only one had all 4 ingredients.” Review, recommendation, offer. This is the persona layer rebuilt as a fictitious publication instead of a fictitious person.
• Persona story pages. A 54-year-old man’s page, a woman’s page. Short UGC video and the long story ad. The part the attorneys general wrote about, still running.

The hooks, in order of how often they appear

1. Mechanism as the story.Four things have to fire in sequence; the blue pill does one. Four failures, four ingredients, one dose.
2. Two numbers.Ten to fifteen minutes. Thirty-six hours. Under the tongue, so a steak dinner does not kill it.
3. “If you don’t qualify, you don’t pay.”The risk reversal sits on the quiz, not the product. The button says Learn more. It never says buy.
4. Age pricing and a veterans tier.Meta-legal segmentation that doubles as a reason to click today.
5. Discretion.No pharmacy, no counter, plain box, no 24-year-old reading your prescription back to you.
6. Anchor and scarcity.“Retail is $179. You’re not paying retail. Wholesale pricing is capped by batch.”

What that means if you were about to build one

• Do not buy GLP-1 traffic at $149. You will be the sixth ad in the feed saying the same thing, against pages that have been running since April.
• Keep GLP-1 as a catalog item, not a campaign. The partner stocks it; the intake sells it. Let search and word of mouth bring the patients who already know what they want.
• Spend the ad budget where there is no $149 floor. Men’s health, testosterone, hair, longevity. The same partner, the same funnel, three to four times the margin per order.
• The rule still holds: he did not invent anything. He saw where the margin went and pointed the machine at it. That is the whole update.

In June the lesson was “say the price first.” In September the lesson is “say it about the product that still has a price.”

Page two, with the lane swapped

1. Lane: men’s health, through the same partner.Ask for their men’s formulary on the first call. Sublingual combinations, tadalafil, sildenafil, testosterone. Set retail above their floor. Expect $130 to $200 kept per order, against $45 to $60 on a monthly GLP-1 plan.
2. Certification first, same as before.LegitScript covers the site, not the drug. Meta’s prescription-drug permission covers the account. Both are required before an ED ad runs, and Meta additionally treats sexual health as restricted: adults only, no explicit imagery, no body focus.
3. Copy the shape, not the tricks.Mechanism, two numbers, risk-free quiz, age pricing, plain box, Learn more. Run every ad from your own brand page with your own face or a released patient. No publication-styled pages, no personas, no “trusted by 50,000 men” you cannot source.
4. The story ad, written honestly.A first-person ad is legal when the person is real and released, or when it is labelled a composite. The structure is on page three: the shame scene, the spouse, the doctors who did not listen, the mechanism, the first night with times on it. Write the true version.
5. Twenty ads, three angles, $50 a day, kill in two weeks.Mechanism, story, review. The build sheet on page three applies unchanged. So does the kill rule.

Compounded ED combinations are compounded drugs. They are not FDA-approved as a combination, and the same misbranding rules that produced the GLP-1 letters apply to every claim you make about them. The clock runs slower in this lane. It still runs.

Where this comes from

• Forma’s read of the Meta Ad Library, US, active ads, September 10, 2026: searches for “medvi” (about 2,200 results), “tirzepatide” with “$149” (about 580), MedVi’s GLP-1 domains (11), and the MEDVi page by page ID. Counts are the Library’s own estimates on that day.
• Forma’s June 2026 pull of 243 MEDVi-related ads, for the before picture.
• Meta advertising standards: prescription drugs; adult products and services; personal health and appearance.
• FDA: warning letters on compounded GLP-1 marketing, 2025 to 2026, linked on page one.

Forma has no connection to MEDVi, QUAD, or any page named here. Ad copy is quoted in short excerpts for analysis. Nothing on this page is medical, legal or financial advice, and none of it is an endorsement of selling compounded medication.